Anders Hallberg

Affibody AB conducts research and development services within biotechnology. It markets and sells licensed products and research findings to the pharmaceutical industry. The company was founded by Karin Nord in 1998 and is headquartered in Stockholm, Sweden.

Lannebo Fonder AB (Lannebo) is an independent fund management firm headquartered in Stockholm, Sweden. The firm was founded in 2000 by Anders Lannebo together with a group of portfolio managers from fund management companies of Nordic banks. Lannebo manages a range of Swedish mutual funds for individuals and institutional clients. Lannebo Fonder is a socially responsible investor and a signatory to the United Nations-supported Principles for Responsible Investment (UNPRI).

Nordea Investment Management AB (NIM) is the Swedish investment management subsidiary of Nordea Asset Management Holding AB, itself a subsidiary of Nordea Bank ABp (HEL: NDA-FI, ADR: NRBAY) in Finland. Founded in 1954 as Merita Nordbanken Investment Management, the firm became Nordea Investment Management AB in 2001 when the Nordea name, an abbreviation of Nordic ideas, replaced Unibank, Nordbanken, Merita and Christiania Bank in a joint renaming operation. Headquartered in Stockholm, NIM manages a range of Swedish funds including pension funds, hedge funds, Luxembourg-domiciled SICAVs and funds registered in other Nordic countries for institutional clients.

Swedbank Robur Fonder AB (Swedbank Robur) is the wholly-owned fund management subsidiary of Swedbank Robur AB, itself a subsidiary of Swedbank AB (STO: SWED.A, ADR: SWDBY) in Sweden. Founded in 1967, the firm is headquartered in Stockholm and manages a range of equity and fixed-income funds for private individuals and institutions including unions, primarily in Sweden. They also provide discretionary account management for institutional clients. Swedbank Robur is a socially responsible investor and signatory to the UN Principles for Responsible Investment (UNPRI).

Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden.

Vasakronan AB operates as a real estate development company. The company owns, develops, and manages commercial properties. Its properties are situated in clusters and offer supplementary services to the tenants. The firm's business activities also include office and retail leasing, and green leases and green offices development. The company was founded in 1955 and is headquartered in Stockholm, Sweden.

Part of Castellum AB, Fastighets Ab Briggen is a Swedish real estate company. The company is based in Oeresund, Sweden. Carl Ola Mattias Orsmark has been the CEO of the company since 2014.

Handelsbanken Fonder AB (HBF) is the wholly-owned fund management subsidiary of Handelsbankens Fondbolagsförvaltning AB, ultimately held by Svenska Handelsbanken AB (STO: SHB-A, ADR: SVNLY) in Swede. The firm is headquartered in Stockholm with offices in Luxembourg, Oslo and Helsinki. Founded in 1959, HBF provides financial advisory and investment management services to private individuals as well as corporate and institutional clients including pension funds. They also manage a range of mutual funds as well as exchange-traded funds. The firm is a responsible investor and signatory to the UN Principles for Responsible Investment (UN PRI).

Carnegie Investment Bank AB is the broker/delear subsidiary of Carnegie Holding AB in Sweden. Headquartered in Stockholm, the firm was founded in 1803 and offers institutional clients several services within research, equity sales and equity capital market transactions (ECM). The Fixed Income unit offers bond research and sales. Carnegie Investment Bank’s research and equity sales enjoy a global position in Nordic equities.

Svenska Handelsbanken AB (Broker) (Handelsbanken-Broker) is the broker/dealer division of Svenska Handelsbanken AB (STO: SHB-A; OTCMKTS: SVNLY) in Sweden. Headquartered in Stockholm, Handelsbanken-Broker was founded in 1871 and provides trading services to large corporates. The firm trades in equities, money market instruments, currencies, commodities and derivatives.

Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna.

Skandinaviska Enskilda Banken AB (Private Banking) (SEB-PB) is the private banking division of Skandinaviska Enskilda Banken AB (ST: SEB) in Sweden. Created in 2007 when SEB Asset Management merged with their private banking business, the firm provides asset management and private banking services to institutions, high-net worth individuals and retail clients from the Nordic countries, the Baltics, Germany, Luxembourg and Poland. Located in Stockholm, the firm has additional offices in the Nordic countries, the Baltics, England, Germany, Luxembourg, Poland, Singapore and Switzerland and has representative offices in France and Spain. SEB-PB offers a full spectrum of wealth management expertise and services, including equity, fixed-income, alternative products, as well as packaging and sales of mutual funds and institutional portfolios.

Proxeon Biosystems ApS develops and sells technology, equipment, and supplies for biotechnology and clinical research. The company was founded by Ole Vorm on October 31, 2002 and is headquartered in Roskilde, Denmark.

SymCel AB develops and markets analytical instrumentations for cell biological research and development. Its products include calScreener, calPlate System, and calView date collection and analysis software. The company was founded by Dan Rolf Stefan Hallen and Bertil Ingemar Wadso in 2004 and is headquartered in Spanga, Sweden.

Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden.

Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden.

SV Health Managers LLP (SVHM) is the investment management subsidiary of SV Life Sciences Advisers LLP in the UK. Established in 2005, the firm was formerly known as SV Life Sciences Managers LLP and changed their name to SV Health Managers LLP in 2017. Based in London, the firm manages the International Biotechnology Trust plc (LSE: IBT), an investment trust vehicle listed on the London Stock Exchange into which corporate and private investors may invest.

SwedenBIO Service AB is a non-profit company that develops biotechnology, diagnostics, pharmaceuticals, and medical technology. It also offers counseling, education, opinion formation, and investigations. The company was founded in 2002 and is headquartered in Stockholm, Sweden.

Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden.

ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden.

KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden.

Part of CellSeed, Inc., Cellseed Sweden AB performs clinical trials. Setsuko Hashimoto has been the CEO of the Swedish company since 2015.

Summa Equity AB (Summa Equity) is a private equity firm founded in 2016 by Jenny Keisu, Reynir Kjær Indahl and Johannes Hidle Lien. The firm is headquartered in Stockholm, Sweden.

Lysa Fonder AB is a private company that offers a fund robot service that automatically invests customers' money at low fees. The company is based in Stockholm, Sweden. The service can be accessed for free through a mobile bank ID. Oscar Björklund has been the CEO of the Swedish company since 2020.

Lumicks BV is a Dutch life science tools company that develops equipment for dynamic single-molecule and cell avidity analysis. The company is based in Amsterdam, NL, and has subsidiaries in the Netherlands and the United States. The company's tools allow researchers to analyze complex biological processes in real-time by applying and measuring forces around biological interactions. Lumicks' C-Trap® optical tweezers and fluorescence & label-free microscopy, and Z-Movi® cell avidity analyzer are used to measure and select immune cells based on their real-time interactions with target cells. Lumicks was founded in 2014 by Olivier Heyning and Andrea Candelli, with Olivier Heyning serving as the CEO since then.

Trill Invest AB is an investment services provider founded in 2020. The private company is based in Stockholm, Sweden. The Swedish company's main focus is on investment services.